SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide

Neurology. 2004 Nov 23;63(10):1977. doi: 10.1212/01.wnl.0000143068.99794.5b.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Acetazolamide / therapeutic use*
  • Adult
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Hypokalemic Periodic Paralysis / drug therapy*
  • Hypokalemic Periodic Paralysis / genetics
  • Male
  • NAV1.4 Voltage-Gated Sodium Channel
  • Palliative Care
  • Physical Exertion
  • Potassium / therapeutic use
  • Sodium Channels / deficiency
  • Sodium Channels / genetics*

Substances

  • Carbonic Anhydrase Inhibitors
  • NAV1.4 Voltage-Gated Sodium Channel
  • SCN4A protein, human
  • Sodium Channels
  • Acetazolamide
  • Potassium